Prediction of cytotoxic activity of a series of 1H-pyrrolo[2,3-b]pyridine derivatives as possible inhibitors of c-Met using molecular fingerprints

被引:5
作者
Damghani, Tahereh [1 ,2 ]
Mashayekh, Korosh [1 ]
Pirhadi, Somayeh [1 ]
Firuzi, Omidreza [1 ]
Sharifi, Shahrzad [1 ]
Edraki, Najmeh [1 ]
Khoshneviszadeh, Mehdi [1 ,2 ]
Avestan, Mohammad Sadegh [3 ]
机构
[1] Shiraz Univ Med Sci, Med & Nat Prod Chem Res Ctr, Shiraz, Iran
[2] Shiraz Univ Med Sci, Sch Pharm, Shiraz, Iran
[3] Univ Cincinnati, Dept Chem, Cincinnati, OH USA
关键词
Cancer; c-Met; docking; molecular dynamics simulation; QSAR; KINASE INHIBITOR;
D O I
10.1080/10799893.2019.1676258
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cancer is a leading cause of death all over the world. HGF/MET signaling pathway is involved in many cancers and its inhibition has great potential as an effective therapeutic intervention. A series of 1H-pyrrolo [2,3-b]pyridine derivatives has recently been identified with cytotoxic activity, and most of them exhibited considerable potencies with IC50 values under 10 mu M. The present study was carried out with the specific aim to shed light upon the quantitative structure activity relationship (QSAR) to design and predict the activity of new potent inhibitors using molecular fingerprints and some 2D and 3D descriptors. The built model was statistically significant in terms of R-2 = 0.90 and R-pred(2) = 0.91 values. Fingerprint PubchemFP759 (1-chloro-2-methylbenzene) was the most effective fragment in the biological activity and just appeared in the most active compound 7j with a pIC(50) value of 8.0. A similarity search study was applied based on compounds 7c and 17e, with reported inhibitory activity against c-Met kinase, which showed that also other compounds could possess similar effects against c-Met enzyme. The most promising compound 7g-cl was subjected to docking and molecular dynamics simulation. Two hydrogen bonds between Lys1110, Met1160, and 7g-cl were stable during the equilibrium time range. The suggested modifications might be considered in future studies to design more efficient anticancer agents.
引用
收藏
页码:295 / 303
页数:9
相关论文
共 23 条
[1]   "NanoBRIDGES" software: Open access tools to perform QSAR and nano-QSAR modeling [J].
Ambure, Pravin ;
Aher, Rahul Balasaheb ;
Gajewicz, Agnieszka ;
Puzyn, Tomasz ;
Roy, Kunal .
CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS, 2015, 147 :1-13
[2]  
[Anonymous], CANC FACTS FIG 2012
[3]   Known and novel roles of the MET oncogene in cancer: a coherent approach to targeted therapy [J].
Comoglio, Paolo M. ;
Trusolino, Livio ;
Boccaccio, Carla .
NATURE REVIEWS CANCER, 2018, 18 (06) :341-358
[4]  
Contrera Joseph F, 2005, Curr Drug Discov Technol, V2, P55, DOI 10.2174/1570163054064684
[5]   Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress [J].
Cui, J. Jean .
JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (11) :4427-4453
[6]   Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK) [J].
Cui, J. Jean ;
Tran-Dube, Michelle ;
Shen, Hong ;
Nambu, Mitchell ;
Kung, Pei-Pei ;
Pairish, Mason ;
Jia, Lei ;
Meng, Jerry ;
Funk, Lee ;
Botrous, Iriny ;
McTigue, Michele ;
Grodsky, Neil ;
Ryan, Kevin ;
Padrique, Ellen ;
Alton, Gordon ;
Timofeevski, Sergei ;
Yamazaki, Shinji ;
Li, Quhua ;
Zou, Helen ;
Christensen, James ;
Mroczkowski, Barbara ;
Bender, Steve ;
Kania, Robert S. ;
Edwards, Martin P. .
JOURNAL OF MEDICINAL CHEMISTRY, 2011, 54 (18) :6342-6363
[7]   Role of the HGF/c-MET tyrosine kinase inhibitors in metastasic melanoma [J].
Demkova, Lucia ;
Kucerova, Lucia .
MOLECULAR CANCER, 2018, 17
[8]   Docking and pharmacophore-based alignment comparative molecular field analysis three-dimensional quantitative structure-activity relationship analysis of dihydrofolate reductase inhibitors by linear and nonlinear calibration methods [J].
Ghasemi, Jahan B. ;
Meftahi, Nastaran ;
Pirhadi, Somayeh ;
Tavakoli, Hossein .
JOURNAL OF CHEMOMETRICS, 2013, 27 (10) :287-296
[9]   Targeting MET in cancer: rationale and progress [J].
Gherardi, Ermanno ;
Birchmeier, Walter ;
Birchmeier, Carmen ;
Woude, George Vande .
NATURE REVIEWS CANCER, 2012, 12 (02) :89-103
[10]  
Jeong H, 2017, GENOME ANNOUNCEMENTS, V5, DOI [10.1128/genomeA.01544-16, 10.1128/genomea.01544-16]